Cooley advised Sucampo Pharmaceuticals on its acquisition of rare disease biotech firm Vtesse for $200 million in cash and stock in upfront payments and contingent payments…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now